Adaptimmune宣布从纳斯达克退市

2025-10-20 19:51

Adaptimmune Therapeutics (NASDAQ:ADAP) has determined to initiate the delisting of its ADS, each representing six ordinary shares from The Nasdaq Capital Market.
The delisting from Nasdaq and deregistration should facilitate cost reductions and further support goal to maximize value going forward.
On October 16, 2025, the Company notified Nasdaq that it intends to file a Form 25 with the SEC on or about October 28, 2025 to effect the voluntary delisting of the Company's ADSs from Nasdaq and to deregister the ADSs. Following confirmation by Nasdaq, the Company currently expects that the trading of its ADSs on Nasdaq will be suspended following the closing of trading on Nasdaq on or about October 27, 2025.
The company had earlier received notice from Nasdaq to regain compliance on minimum bid price requirement of $1.00 per share until December 1, 2025.
The Company currently expects that its ADSs will be quoted on the OTC Pink Limited Market, a market operated by OTC Markets Group.
Shares -3%.
Source: Press Release

More on Adaptimmune